{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:08:09Z","timestamp":1791414489648,"version":"4.3.3"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.bmcl.2022.128759","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T20:18:33Z","timestamp":1650917913000},"page":"128759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["In silico, synthesis and anticancer evaluation of benzamide tryptamine derivatives as novel eEF2K inhibitors"],"prefix":"10.1016","volume":"67","author":[{"given":"Zedong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinda","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128759_b0005","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2022.128759_b0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.acr.2018.02.003","article-title":"Chapter three-acquired resistance to drugs targeting tyrosine kinases","volume":"138","author":"Rosenzweig","year":"2018","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128759_b0015","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1074\/jbc.272.11.6846","article-title":"Mapping of the novel protein kinase catalytic domain of dictyostelium myosin II heavy chain kinase A","volume":"272","author":"Cote","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2022.128759_b0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jbior.2014.04.003","article-title":"Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles","volume":"55","author":"Kenney","year":"2014","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.bmcl.2022.128759_b0025","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3390\/ijms22052408","article-title":"Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy","volume":"22","author":"Zhang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2022.128759_b0030","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1042\/BST20140323","article-title":"Regulation and roles of elongation factor 2 kinase","volume":"43","author":"Proud","year":"2015","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.bmcl.2022.128759_b0035","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1017\/cjn.2016.336","article-title":"OS5-173 Inhibition of eEF2K as a novel therapeutic strategy in neuroblastoma and medulloblastoma","volume":"43","author":"Delaidelli","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.bmcl.2022.128759_b0040","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.15252\/emmm.201404402","article-title":"Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K","volume":"6","author":"Liu","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.bmcl.2022.128759_b0045","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/15384101.2016.1254974","article-title":"Translating the anticancer properties of eEF2K","volume":"16","author":"Gassart","year":"2017","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bmcl.2022.128759_b0050","doi-asserted-by":"crossref","first-page":"15541","DOI":"10.1074\/jbc.M700702200","article-title":"Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kr\u00fcppel-like factor 5","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2022.128759_b0055","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ijc.32560","article-title":"Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K\/Akt and STAT3","volume":"146","author":"Zhou","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bmcl.2022.128759_b0060","doi-asserted-by":"crossref","first-page":"41970","DOI":"10.1074\/jbc.M302403200","article-title":"Myocardial ischemia and increased heart work modulate the phosphorylation state of eukaryotic elongation factor-2","volume":"278","author":"Horman","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2022.128759_b0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2018.07.027","article-title":"Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer","volume":"124","author":"Bircan","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bmcl.2022.128759_b0070","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00109-020-01917-8","article-title":"Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target","volume":"98","author":"Karakas","year":"2020","journal-title":"J Mol Med"},{"key":"10.1016\/j.bmcl.2022.128759_b0075","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10495-013-0927-2","article-title":"Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells","volume":"19","author":"Ashour","year":"2014","journal-title":"Apoptosis"},{"key":"10.1016\/j.bmcl.2022.128759_b0080","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.cellsig.2016.01.005","article-title":"Elongation factor 2 kinase promotes cell survival by inhibiting protein synthesis without inducing autophagy","volume":"28","author":"Moore","year":"2016","journal-title":"Cell Signal"},{"key":"10.1016\/j.bmcl.2022.128759_b0085","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1073\/pnas.94.10.4884","article-title":"Identification of a new class of protein kinases represented by eukaryotic elongation factor-2 kinase","volume":"94","author":"Ryazanov","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2022.128759_b0090","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-021-00124-5","article-title":"eEF2K: an atypical kinase target for cancer","volume":"20","author":"Temme","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2022.128759_b0095","first-page":"6894","article-title":"Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines","volume":"63","author":"Arora","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128759_b0100","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/S0968-0896(02)00160-8","article-title":"TX-1123: An antitumor 2-hydroxyarylidene-4-cyclopentene-1,3-dione as a protein tyrosine kinase inhibitor having low mitochondrial toxicity","volume":"10","author":"Hori","year":"2002","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2022.128759_b0105","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1016\/j.bmc.2014.06.050","article-title":"Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors","volume":"22","author":"Edupuganti","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2022.128759_b0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0304-4165(00)00061-1","article-title":"Novel compounds, \u20181,3-selenazine derivatives\u2019 as specific inhibitors of eukaryotic elongation factor-2 kinase","volume":"1475","author":"Cho","year":"2000","journal-title":"Biochim Biophys Acta (BBA) Gen Subj"},{"key":"10.1016\/j.bmcl.2022.128759_b0115","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0040-4020(01)01170-X","article-title":"Leptosins M-N1, cytotoxic metabolites from a Leptosphaeria species separated from a marine alga. Structure determination and biological activities","volume":"58","author":"Yamada","year":"2002","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bmcl.2022.128759_b0120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.apsb.2016.04.002","article-title":"A high-throughput screening assay for eukaryotic elongation factor 2 kinase inhibitors","volume":"6","author":"Xiao","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmcl.2022.128759_b0125","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ejmech.2017.11.065","article-title":"Design, synthesis and structure-activity relationship of a focused library of \u03b2-phenylalanine derivatives as novel eEF2K inhibitors with apoptosis-inducing mechanisms in breast cancer","volume":"143","author":"Guo","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128759_b0130","doi-asserted-by":"crossref","first-page":"19097","DOI":"10.1039\/C9NJ02600B","article-title":"Virtual screening and experimental validation of eEF2K inhibitors by combining homology modeling, QSAR and molecular docking from FDA approved drugs","volume":"43","author":"Ye","year":"2019","journal-title":"New J Chem"},{"key":"10.1016\/j.bmcl.2022.128759_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105296","article-title":"Novel inhibitors of eukaryotic elongation factor 2 kinase: In silico, synthesis and in vitro studies","volume":"116","author":"Onder","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2022.128759_b0140","doi-asserted-by":"crossref","first-page":"ra17-ra17","DOI":"10.1126\/scisignal.2000525","article-title":"Crystal structure of the \u03b1-kinase domain of dictyostelium myosin heavy chain kinase A","volume":"3","author":"Ye","year":"2010","journal-title":"Sci Signal"},{"key":"10.1016\/j.bmcl.2022.128759_b0145","doi-asserted-by":"crossref","first-page":"26634","DOI":"10.1038\/srep26634","article-title":"Structure of the dictyostelium myosin-II Heavy chain kinase A (MHCK-A) \u03b1-kinase domain apoenzyme reveals a novel autoinhibited conformation","volume":"6","author":"Ye","year":"2016","journal-title":"Sci Rep"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22002359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22002359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:45:10Z","timestamp":1760773510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22002359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":29,"alternative-id":["S0960894X22002359"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128759","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico, synthesis and anticancer evaluation of benzamide tryptamine derivatives as novel eEF2K inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128759"}}